July 15, 2025

Table 4 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

View Full Paper

Ask AI

Bookmark

MAIN FINDING: The study evaluates the effectiveness of CDK2/4/6 inhibitor PF-06873600 in breast cancer patients.
KEY EVIDENCE: Best overall and confirmed objective responses were assessed using RECIST criteria by investigators.
APPROACH: This was a phase I/IIa study involving a response-evaluable set of breast cancer patients.
SIGNIFICANCE: Results suggest CDK2/4/6 inhibitors may enhance treatment outcomes when combined with endocrine therapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Phase I/IIa study shows overall and objective responses in breast cancer patients, indicating potential benefits of CDK2/4/6 inhibitors with endocrine therapy.

Cite This Study

Yap et al. (2025) studied this question.

synapsesocial.com/papers/689a02bce6551bb0af8cc6aa https://doi.org/10.1158/1078-0432.29568350

View Full Paper

Ask AI

Bookmark

Implication

Phase I/IIa study shows overall and objective responses in breast cancer patients, indicating potential benefits of CDK2/4/6 inhibitors with endocrine therapy.

Table 4 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

Key Points

Discussion

Implication

Cite This Study

Table 4 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider